A Year of Progress and Development at Westbourne
The world is changing fast, with new technologies and ways of working transforming all aspects of business. These changes apply as much in the pharmaceutical industry as any other, with the drivers of change ranging from maintaining competitiveness to ensuring ongoing compliance.
At Westbourne, we are responding to these changes internally in addition to facilitating change for our customers. As a result, 2024 has been a year of progress and development at Westbourne.
John O’Sullivan is Westbourne’s founder and CEO. John said: “One of the most visible changes at Westbourne over 2024 is the launch of our new logo and website. Both have been modernised to better reflect our brand and our unique value proposition as an IT services provider that specialises in solutions for customers in the pharmaceutical industry.
“The new website also highlights how we are evolving as a business to meet the needs of our pharmaceutical industry customers. This includes expanding our scientific capabilities to support the requirements of pharmaceutical laboratories.
“We are achieving this expansion of our capabilities by upskilling our technical resources in critical scientific areas, in addition to recruiting new staff in chemist and quality control roles.
“The ability to provide a unique blend of technical and scientific skills and resources has enabled us to successfully address the challenges faced by our pharma industry customers.
“With new customers coming on board, we will continue to refine and enhance our blended technical and scientific solutions in 2025 and beyond.”
2024 Reflections
John highlighted some of the key milestones and events at Westbourne throughout 2024. He said: “In addition to the launch of our new website and logo, we also achieved a listing in the IDA Service Directory. This listing is further proof of our experience working with multinational companies, especially those in the pharmaceutical industry.
“Our team was also busy throughout the year, with one of the highlights being our sponsorship of the Pharma & MedTech Expo in Dublin in May where we delivered a keynote speech on digital transformation in pharmaceutical laboratories.
“We also attended many other events, and we were shortlisted for several prestigious 2024 life sciences sector awards.”
Looking Forward to 2025
“While reflecting proudly on our achievements in 2024, we are also looking forward to the coming year excited to continue building even stronger relationships with our valued customers.
“I would like to thank the Westbourne team for their hard work and dedication throughout 2024. While we deal with technology and, increasingly, scientific processes, Westbourne is a people business, and our successes are down to our team.
“I would also like to thank all our customers, suppliers, and partners for their support, and I want to wish you a happy holiday season and a safe and prosperous New Year.”
Latest Insights
Case Study: Implementing a Computer System Validation Policy for a Pharmaceutical Company
Implementing a robust Computer System Validation (CSV) policy is crucial for ensuring compliance in pharmaceutical manufacturing and laboratory operations. Effective CSV policies also enhance operational efficiency, quality, and productivity. Regulators like the FDA...
Q&A On Digital Transformation in the Pharma Lab – Where to Start and How to Navigate the Pitfalls
Later this month, Westbourne IT Head of Sales and Marketing, Dennis Blanck, will be speaking at the Pharma &...
Choosing a Global Service Desk Solution for Your Irish Pharmaceutical Facility
Whether you are an Irish pharmaceutical company, a multinational corporation with lab and/or manufacturing facilities...
A Realistic Roadmap for Digital Transformation in Labs
Buzzwords like the Lab of the Future and Lab 5.0 are becoming increasingly common. They each come back to a concept...
There’s an IT/OT Gap in Your Pharmaceutical Laboratory. Here’s How to Bridge It
Digital transformation is on the agenda for all pharmaceutical companies as the option of standing still simply isn't...